Comparing the current results to its competitors, Theralink Technologies Inc reported Revenue increase in the 1 quarter 2023 by 51.82 % year on year. The sales growth was above Theralink Technologies Inc 's competitors' average revenue growth of 16.45 %, achieved in the same quarter.
Due to outstanding performance in Overall company, revenue grew by 51.82 % Theralink Technologies Inc improved its market share, to approximately 0.01 %.
Publicly Traded Peers of Theralink Technologies Inc
Accustem Sciences Inc Share Performance
-91.88%
One Year
Accustem Sciences Inc
Profile
Accustem Sciences Inc is a company that operates on a subscription-based business model with a focus on providing personalized health solutions. They offer genetic testing services and use the results to create customized plans, including nutrition and exercise recommendations, to improve overall health and prevent diseases. The company aims to enhance the well-being of individuals by leveraging genetic insights and promoting proactive health management.
Biocept Inc is a molecular diagnostics company that specializes in developing and commercializing liquid biopsy tests. Their business model revolves around utilizing their proprietary technologies to detect and analyze biomarkers in blood samples, enabling physicians to make more informed treatment decisions for patients with cancer. They collaborate with various pharmaceutical and biotech companies to conduct clinical studies and molecular testing, offering their expertise and services in the field of precision medicine.
Exact Sciences Corporation is a medical diagnostics company that specializes in early cancer detection. Their business model involves developing and commercializing non-invasive, DNA-based tests for the detection of colorectal cancer, as well as other cancers and diseases. By leveraging advanced technology and partnerships with healthcare providers, Exact Sciences aims to improve patient outcomes through early detection and intervention.
Guardant Health Inc's business model revolves around providing advanced genomic testing services for cancer patients. It specializes in developing liquid biopsy tests that analyze circulating tumor DNA (ctDNA) in the blood. These tests help in early cancer detection, treatment selection, and monitoring of cancer progression. Guardant Health Inc collaborates with healthcare providers, pharmaceutical companies, and researchers to provide these innovative tests and contribute to the advancement of precision medicine in oncology.
Myriad Genetics Inc's business model revolves around providing molecular diagnostic testing services and developing innovative precision medicine solutions that help identify and personalize treatment options for patients across various medical specialties.
Sources:
Theralink Technologies Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Theralink Technologies Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
